2-(pyridin-2-ylamino)pyrimidine | 64682-29-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2-(pyridin-2-ylamino)pyrimidine
• 英文别名: N-(pyridin-2-yl)pyrimidin-2-amine；2-pyridyl-2-pyrimidylamine；pyridin-2-yl-pyrimidin-2-yl-amine；[2]Pyridyl-pyrimidin-2-yl-amin；2-Pyrimidinamine, N-2-pyridinyl-；N-pyridin-2-ylpyrimidin-2-amine
• CAS: 64682-29-7
• 化学式: C₉H₈N₄
• mdl: MFCD00477237
• 分子量: 172.189
• InChiKey: LMZLTBMBIZUPOS-UHFFFAOYSA-N

物化性质

• 熔点：
  150.2-152.1 °C
• 沸点：
  364.2±34.0 °C(Predicted)
• 密度：
  1.274±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(pyridin-2-ylamino)pyrimidine 、 sodium perchlorate 、 palladium dichloride 以 乙醇 、 水 为溶剂， 以65%的产率得到bis(2-pyridyl-2-pyrimidylamine)palladium(II) perchlorate
  参考文献：
  名称：

  摘要：

  Ionic [Pd(LH)(2)(ClO4)(2)] and neutral (PdL2) complexes of Pd(II) with hetarylamines derived from dipyridylamine and benz[c,d]indolylamine were synthesized. The H-1 NMR, IR, and UV spectra of the products were studied. Irradiation of neutral Pd(II) complexes with N-derivatives of benz[c,d]indolylamine results in ligand elimination. Photolysis of a neutral Pd(II) complex with 3,5-dichloro-2,2 ' -dipyridylamine in solution results in ligand cyclization to give 8-chlorodipyrido[1,2-a:2 ' ,3 ' -d]imidazole.

  DOI：

  10.1023/a:1012347304871
• 作为产物：
  描述：

  2-Aminopyridine N-Oxide 在 palladium 10% on activated carbon 、 甲酸铵 、 对甲苯磺酸 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 26.0h， 生成 2-(pyridin-2-ylamino)pyrimidine
  参考文献：
  名称：

  基于新型 aza-Smiles 重排的氨基吡啶 1 - 氧化物及其 N 保护衍生物连续胺化杂芳族卤化物

  摘要：

  摘要 描述了 SNAr 和 Pd 催化的吖嗪、二嗪和三嗪的氯衍生物与 2-氨基吡啶 1-氧化物及其 N-保护衍生物的胺化。

  DOI：

  10.1515/hc-2012-0139

文献信息

• [EN] DERIVATIVES OF 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-N-(PYRIDIN-3-YL) PYRIMIDIN-2- AMINE FOR TREATING PROLIFERATIVE DISEASES AND CONDITIONS<br/>[FR] DÉRIVÉS DE 4-(IMIDAZO[1,2-A] PYRIDIN-3-YL)-N-(PYRIDIN-3-YL)PYRIMIDIN-2-AMINE POUR LE TRAITEMENT DE MALADIES ET D'AFFECTIONS PROLIFÉRATIVES
  申请人：AUCENTRA THERAPEUTICS PTY LTD

  公开号：WO2021072475A1

  公开（公告）日：2021-04-22

  A novel class of heteroaryl compounds for use in the prevention and/or treatment of proliferative diseases and conditions including cancers. The compounds are considered to be capable of inhibiting cell proliferation by inhibiting the activity of one or more protein kinases selected from CDKs such as CDK2, CDK4, CDK6 and/or CDK9, and/or other protein kinases such as FLT3 and its mutants. The compounds have the general structure I: (I)

  一类新型的杂环芳基化合物，用于预防和/或治疗包括癌症在内的增殖性疾病和症状。这些化合物被认为能够通过抑制细胞增殖来抑制细胞蛋白激酶的活性，所选的蛋白激酶包括CDKs（如CDK2、CDK4、CDK6和/或CDK9）以及其他蛋白激酶，如FLT3及其突变体。这些化合物具有一般结构I：（I）
• [EN] DIARYLAMINE-SUBSTITUTED QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS<br/>[FR] QUINOLONES SUBSTITUÉES PAR DIARYLAMINE UTILES COMME INHIBITEURS DE L'OXYDE NITRIQUE SYNTHASE INDUCTIBLE.
  申请人：KALYPSYS INC

  公开号：WO2009029617A1

  公开（公告）日：2009-03-05

  Novel diarylamine-substituted quinolone compounds and pharmaceutical compositions, certain of which have been found to inhibit inducible NOS synthase have been discovered, together with methods of synthesizing and using the compounds including methods for the treatment of iNOS-mediated diseases in a patient by administering the compounds.

  已发现新的含有二芳胺基取代喹诺酮化合物和药物组合物，其中一些已被发现能抑制诱导型NOS合成酶，还包括合成和使用这些化合物的方法，包括通过给患者施用这些化合物治疗iNOS介导的疾病的方法。
• CRYSTALLINE FORMS OF MESYLATE SALT OF PYRIDINYL AMINO PYRIMIDINE DERIVATIVE, PREPARATION METHODS THEREFOR, AND APPLICATIONS THEREOF
  申请人：SHANGHAI ALLIST PHARMACEUTICALS, INC.

  公开号：US20190092753A1

  公开（公告）日：2019-03-28

  Forms I and II of the mesylate salt of the compound of formula (I), a preparation methods thereof, a pharmaceutical composition containing the crystal forms, and the use of the crystal forms in treating diseases mediated by activating and resistance mutations of EGFR, in particular cancer, in mammal, in particular in human. The crystal forms of the mesylate salt of the compound of formula (I) have good solubilities and high bioavailabilities in animals.

  化合物的甲磺酸盐的I和II形式，其制备方法，含有晶体形式的药物组合物，以及利用这些晶体形式治疗由激活和耐药EGFR突变介导的疾病，尤其是癌症，在哺乳动物中，特别是在人类中。这种化合物的甲磺酸盐的晶体形式在动物体内具有良好的溶解度和高生物利用度。
• 2- (2-pyridyl) -5-phenyl-6-aminopyrimidine, method and intermediate products for the production and use thereof for combating noxious fungi
  申请人：Schieweck Frank

  公开号：US20050107401A1

  公开（公告）日：2005-05-19

  The invention relates to 2-(2-pyridyl)-5-phenyl-6-amninopyrimidines of formula I, wherein the substitutes and the index have the following meaning: R 1 represents halogen, hydroxy, hyano, hxo, nitro, amino, mercapto, alkyl, halogenalkyl, alkenyl, alkinyl, cycloalkyl, alkoxy, halogenalkoxy, carboxyl, alkoxycarbonyl, carbamoyl, alkylaminocarbonyl, dialkylamincarbonyl, morpholinocarbonyl, pyrrolidinocarbonyl, alkylcarbonylamino, alkylamino. dialkylamino, alkylthio, alkylsulfinyl, alkylsulfonyl, hydroxysulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl; m=0 or 1-4; R 2 represents hydrogen, halogen, cyano, alkyl, halogenalkyl or alkoxy; R 3 , R 4 represents hydrogen, alkyl, halogenalkyl, cycloalkyl, halogencycloalkyl, alkenyl, halogenalkenyl, cycloalkenyl, alkinyl, halogenalkinyl or cycloalkinyl, R 3 and R 4 together with the nitrogen atom to which they are connected, form a five or six-membered ring which is interrupted by an atom from the group O, N or S and/or can be substituted according to the description; R 5 represents halogen, alkyl or halogenalkyl; R 6 represents hydrogen or one of the known groups in R 5 ; R 7 , R 8 represent hydrogen, halogen, alkyl or halogenalkyl; R 9 represents hydrogen, halogen, hydroxy, cyano, alkyl, alkoxy, cycloalkoxy, halogenalkoxy, alkoxycarbonyl or alkylaminocarbonyl. The invention also relates to a method and intermediate product for the production of said compound in addition to the use thereof for combating undesirable plants.

  本发明涉及式I的2-(2-吡啶基)-5-苯基-6-氨基嘧啶，其中取代基和索引具有以下含义：R1表示卤素、羟基、氰基、氢氧基、硝基、氨基、巯基、烷基、卤代烷基、烯基、炔基、环烷基、烷氧基、卤代烷氧基、羧基、烷氧羰基、氨基甲酰基、二烷基氨基甲酰基、吗啉基甲酰基、吡咯烷基甲酰基、烷基羰基氨基、烷基氨基、二烷基氨基、烷基硫基、烷基亚磺酰基、烷基磺酰基、羟基磺酰基、氨基磺酰基、烷基氨基磺酰基、二烷基氨基磺酰基；m=0或1-4；R2表示氢、卤素、氰基、烷基、卤代烷基或烷氧基；R3、R4表示氢、烷基、卤代烷基、环烷基、卤代环烷基、烯基、卤代烯基、环烯基、炔基、卤代炔基或环炔基，R3和R4与它们连接的氮原子一起形成一个由O、N或S组成的五元或六元环，该环被中断并且可以根据说明进行取代；R5表示卤素、烷基或卤代烷基；R6表示氢或R5中已知的一种基团；R7、R8表示氢、卤素、烷基或卤代烷基；R9表示氢、卤素、羟基、氰基、烷基、烷氧基、环烷氧基、卤代烷氧基、烷氧羰基或烷基氨基羰基。本发明还涉及一种制备所述化合物的方法和中间体以及用于防治不良植物的用途。
• Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
  申请人：Wang Shudong

  公开号：US20060241297A1

  公开（公告）日：2006-10-26

  The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein: (A) “a” is a single bond and “b” is a double bond; R 1 and R 2 are each independently as defined below; R 10 is absent; or (B) “a” is a double bond and “b” is a single bond; R 1 is oxygen; R 2 is as defined below; and R 10 is H or alkyl; X is S, O, NH, or NR 7 ; Y is N or CR 8 ; one of Z 1 , Z 2 , and Z 3 is N or N + R a and the remainder are each independently CR 7 ; R 1 , R 2 , R 5 and R 6 are each independently R 7 ; R 3 and R 4 are each independently R 8 ; each R 7 is independently H, halogen, NR b R c , OR d or a hydrocarbyl group optionally substituted by one or more R 9 groups; each R 8 is independently H or (CH 2 ) n R 9 , where n is 0 or 1; each R 9 is independently selected from H, halogen, NO 2 , CN, R e , NHCOR f , CF 3 , COR g , NR h R i , CONR j R k , SO 2 NR l R m , SO 2 R n , OR p , OCH 2 CH 2 OR q , morpholine, piperidine and piperazine; and R a-q are each independently H or alkyl, wherein said alkyl group is optionally substituted by one or more R 9 groups; where the compound is other than [4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-yl]-pyridin-2-yl-amine and 4-[4-fluorophenyl)-1-(1-methyl-4-piperidinyl)-1H-imidazol-5-yl]-N-4-pyridinyl-2-pyrimidinamine. Further aspects of the invention relate to the use of compounds of formula I in the treatment of proliferative disorders, viral disorders, CNS disorders, strokes, alopecia and/or diabetes.

  本发明涉及式I的化合物或其药学上可接受的盐，其中：（A）“a”为单键，“b”为双键；R1和R2分别如下所定义；R10不存在；或（B）“a”为双键，“b”为单键；R1为氧原子；R2如下所定义；R10为H或烷基；X为S、O、NH或NR7；Y为N或CR8；Z1、Z2和Z3中的一个为N或N+Ra，其余分别独立为CR7；R1、R2、R5和R6分别独立为R7；R3和R4分别独立为R8；每个R7独立地为H、卤素、NRbRc、ORd或一个或多个R9基团选择性取代的烃基；每个R8独立地为H或（CH2）nR9，其中n为0或1；每个R9独立地选择自H、卤素、NO2、CN、Re、NHCORf、CF3、CORg、NRhRi、CONRjRk、SO2NRlRm、SO2Rn、ORp、OCH2CH2ORq、吗啡啶、哌啶和哌嗪；而Ra-q独立地为H或烷基，其中所述的烷基可以选择性地被一个或多个R9基团取代；其中该化合物不是[4-(2,4-二甲基噻唑-5-基)嘧啶-2-基]-吡啶-2-基胺和4-[4-氟苯基)-1-(1-甲基-4-哌啶基)-1H-咪唑-5-基]-N-4-吡啶基-2-嘧啶胺。本发明的另一方面涉及将式I的化合物用于治疗增殖性疾病、病毒性疾病、中枢神经系统疾病、中风、脱发和/或糖尿病。